By Colin Kellaher
Mineralys Therapeutics shares surged to a new 52-week high Monday after the clinical-stage biopharmaceutical company reported positive study results for its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.
Shares of the Radnor, Pa., company were recently changing hands at $15.07, up 43%, after touching a 52-week high of $15.64 early in the session.
Mineralys said a pair of pivotal studies of lorundrostat achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints, and that the results demonstrate the opportunity for the drug in third-line or later treatment.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 10, 2025 09:57 ET (13:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。